Menace Elbow: Disseminated Nocardiosis - 29/10/18
Doi : 10.1016/j.amjmed.2018.04.012
Rupak Datta, MD, PhD a, ⁎ 
, Erik Kramer, BA b, Harald Reinhart, MD a, e, Sheldon Campbell, MD, PhD c, f, Ellice Wong, MD d, g, Shaili Gupta, MD a, e
, Erik Kramer, BA b, Harald Reinhart, MD a, e, Sheldon Campbell, MD, PhD c, f, Ellice Wong, MD d, g, Shaili Gupta, MD a, e a Section of Infectious Diseases, Yale School of Medicine, New Haven, Conn
b Department of Internal Medicine, Yale School of Medicine, New Haven, Conn
c Department of Laboratory Medicine, Yale School of Medicine, New Haven, Conn
d Division of Medical Oncology, Yale School of Medicine, New Haven, Conn
e Division of Infectious Diseases, VA Connecticut Health Care, West Haven
f Pathology and Laboratory Medicine, VA Connecticut Health Care, West Haven
g Division of Hematology and Oncology, VA Connecticut Health Care, West Haven
⁎Requests for reprints should be addressed to Rupak Datta, MD, PhD, Section of Infection Diseases, Yale School of Medicine, PO Box 208022, New Haven, CT 06520.Section of Infection DiseasesYale School of MedicinePO Box 208022New HavenCT06520
Thomas J. Marrie, MD, Section Editor
Plan
| Funding: Grant number 2T32AI007517-16 supported this work at Yale School of Medicine's Section of Infectious Diseases. The funding source had no role in the study design; data collection, analysis, and interpretation; manuscript preparation; or in the decision to submit the article for publication. |
|
| Conflicts of Interest: None. |
|
| Authorship: All authors had access to the data and a role in writing the manuscript. |
© 2018
Publié par Elsevier Masson SAS.
Vol 131 - N° 11
P. 1307-1309 - novembre 2018 Retour au numéro
Article précédent
- New Injectable Agents for the Treatment of Type 2 Diabetes Part 2—Glucagon-Like Peptide-1 (GLP-1) Agonists
- Christa George, AhYoung Byun, Amanda Howard-Thompson
- A Vanishing Entity: Rheumatoid Vasculitis
- Joel Horton, Anand Kumthekar
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?